Floatz logo

Medroxyprogesterone

Cardiovascular Disorder

Peking Union Medical College HospitalSmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

55 Active assets in the Cardiovascular Disorder cohort.

Asset / SponsorPhaseRating
Aspirin
AstraZeneca
Phase 4BBB
Liraglutide
University of Sao Paulo General Hospital
Phase 4BBB
ATORVASTATIN
Duke University
Phase 4BBB
Rosuvastatin
Nanjing First Hospital, Nanjing Medical University
Phase 4BBB
SIMVASTATIN
McMaster University
Phase 4BBB

View all 50 →

Same molecule, other indications

Medroxyprogesterone is also rated in:

osteoporosisDormant
BBB
Indicative · Phase 4
72 / 100
View asset →
sickle cell diseaseActive
BB
Indicative · Phase 4
65 / 100
View asset →
prostate adenocarcinomaDormant
BB
Indicative · Phase 3
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →